Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, could downregulate NGF, relieving chronic pain due to head and neck squamous cell carcinoma (HNSCC) (Yang et al. 2015a, b). This evidence concerns the gene PTGS2 and head and neck squamous cell carcinoma.